Jan. 27, 2026 — Cytokinetics, Inc. has announced that Myqorzo (aficamten) is now available for prescription in 5 mg, 10 mg, 15 mg and 20 mg tablets in the U.S. Myqorzo was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.
Experience the full interactive Multichannel News Release here: www.multivu.com/cytokinetics/9379451-en-myqorzo-now-available-ohcm.
Myqorzo is a once-daily, oral allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction.
“With Myqorzo now available in the U.S., we are delivering on our long-standing commitment to patients living with obstructive HCM and turning the page onto a new chapter as a commercial biopharmaceutical company,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “This product launch is the culmination of decades of rigorous science, clinical development, and commercial readiness preparations, reflecting our unwavering commitment to making a meaningful difference in the lives of patients.”
The full U.S. Prescribing Information for Myqorzo includes a Boxed WARNING for the risk of heart failure. MYQORZO reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction. Echocardiogram assessments are required prior to and during treatment with MYQORZO to monitor for systolic dysfunction. Initiation of Myqorzo in patients LVEF <55% is not recommended. Decrease the dose of Myqorzo if LVEF <50% and ≥40%. Interrupt the dose of Myqorzo if LVEF <40% or if the patient experiences heart failure symptoms or worsening clinical status due to systolic dysfunction. Because of the risk of heart failure due to systolic dysfunction, Myqorzo is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MYQORZO REMS Program. Please see additional Important Safety Information including Boxed WARNING below.
Cytokinetics received U.S. FDA approval for Myqorzo on Dec. 19, 2025. The approval was based on the positive results from the pivotal Phase 3 clinical trial, SEQUOIA-HCM, published in the New England Journal of Medicine.1
Cytokinetics is committed to supporting patients with Myqorzo & You, a personalized program for patients prescribed Myqorzo in the U.S. to help navigate the treatment journey, provide disease and product education, and offer support with insurance benefits investigations or financial assistance for those eligible.
- Maron, MS, et al. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. doi:10.1056/NEJMoa2401424
April 20, 2026 
